Robot-assisted Walking Treatment in Hereditary Spastic Paraplegia (HSP)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age4-70
SponsorIRCCS Eugenio Medea

About this trial

Patients will undergo a combined rehabilitation treatment consisting of 15 sessions on Lokomat and 15 sessions of physical therapy over three weeks for a total of 30 sessions. Two sessions/day for 5 days a week. The same subjects will conduct clinical-functional assessments before, at the end of treatment, and after a 3-month follow-up:

3D Gait Analysis with defined protocol (BTSBioenginner); Spastic Paraplegia Rating Scale (SPRS); Six-Minute Walk Test (6MWT), Ten Meters Walk Test (10MWT), Gross Motor Function Measure-88 (GMFM-88) and Berg Balance Scale (BBS); Quality of life questionnaires: Medical Outcome Survey Short Form (SF-36) and ad hoc questionnaire for subjective assessment of symptoms during walking (HSP-SNAP).

This study is part of normal clinical practice and does not involve any changes to the current rehabilitation course for patients.

Eligibility criteria

Qualifiers

genetic or clinical diagnosis of HSP.

age greater than 4 years and less than 70

femur length > 23 cm

ability to walk independently indoors, with or without walking aids.

Disqualifiers

botulinum toxin injection or lower limb surgery in the previous 6 months

severe lower limb muscle retractions

severe osteoporosis

unhealed skin lesions in lower limbs

Trial design

Treatments tested in this trial

  • Robot-Assisted Gait Training

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators